Bromperidol decanoate (depot) for schizophrenia

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• Antipsychotic medications are standard treatment for schizophrenia.
• Long-acting injectable antipsychotics, like bromperidol decanoate, are used for maintenance therapy.

Purpose of the Study:

• To evaluate depot bromperidol against placebo, oral antipsychotics, and other depot antipsychotics.
• Assess clinical, social, and economic outcomes in schizophrenia patients.

Main Methods:

• Searched the Cochrane Schizophrenia Group Register for randomized trials.
• Included trials comparing depot bromperidol with placebo, oral antipsychotics, or other depot preparations.
• Primary outcomes included global function, service utilization, and relapse rates.

Main Results:

• No new studies were found in the 2012 update.
• Bromperidol decanoate showed no clear difference from placebo for adverse effects.
• Fewer relapses occurred with fluphenazine and haloperidol decanoate compared to bromperidol decanoate.
• Patients left the bromperidol decanoate group more frequently due to any cause.

Conclusions:

• Limited data suggest bromperidol decanoate may be superior to placebo but inferior to fluphenazine or haloperidol decanoate.
• Bromperidol decanoate could be a viable option if other depots are contraindicated.
• High-quality, well-reported randomized trials are necessary to guide clinical practice.